NCT01385293View on ClinicalTrials.gov

BKM120 in Metastatic Castration-resistant Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions
Prostate CancerMetastatic (Spread to Other Areas of the Body)
Interventions
DRUG

BKM120

BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily

Trial Locations (3)

27710

Duke Cancer Institute, Durham

97239

OHSU Knight Cancer Institute, Portland

98109

University of Washington, Seattle

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Andrew J. Armstrong, MD

OTHER